Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGARFiled 9 h ago

Insulet (PODD) reports a director or officer change

Open the sourceReported by SEC EDGAR, sec.gov, 20 November 2026, by SEC EDGAR

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Insulet Corporation (PODD) disclosed in a November 20, 2026 Form 8-K that its board appointed Michael R. Minogue as a Class I director effective that day, returning him to a seat he held from August 2017 until his September 2026 resignation to focus on his Massachusetts gubernatorial candidacy. Minogue, former chairman, president and CEO of Abiomed until its December 2022 sale and a former GE Healthcare executive, will serve a term expiring at the 2029 annual meeting and receive an initial restricted stock unit grant worth about $121,700, the pro-rated portion of the $260,000 annual non-employee director equity award. The filing states there are no arrangements or understandings between Minogue and other persons regarding his selection and no related-party transactions requiring disclosure. The appointment restores medical-device industry experience to Insulet's board as the diabetes technology maker navigates a competitive pump and sensor market. Investors will watch whether Minogue's return precedes further board or leadership changes and how the company frames his role in strategic oversight.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR's report. It can get details wrong, so check the source.

Named in this story

Insulet Corporation, Michael R. Minogue, Insulet (PODD), Abiomed, Inc., General Electric Healthcare

A linked name opens that asset's sentiment page.